^
    BIOMARKER:

    BRAF V600E

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Entrez ID:
    673
    Related biomarkers:
    Mutation
    CNA
    Fusion
    Others
    BRAF V600E
    Hairy Cell Leukemia
    trametinib + dabrafenib
    Sensitive
    :
    C3
    Blood - 1 week - (New C3)
    BRAF V600E
    Colorectal Cancer
    cetuximab + encorafenib + binimetinib
    Sensitive
    :
    A1
    ESMO 2022 - 3 weeks - (New C3)
    BRAF V600E
    Thyroid Gland Papillary Carcinoma
    trametinib + dabrafenib
    Sensitive
    :
    C1
    ESMO 2022 - 3 weeks - (New C3)
    BRAF V600E
    Colorectal Cancer
    cetuximab + encorafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Non Small Cell Lung Cancer
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Thyroid Gland Anaplastic Carcinoma
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Thyroid Gland Anaplastic Carcinoma
    dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    vemurafenib + cobimetinib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    vemurafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    trametinib
    Sensitive
    :
    A1
    BRAF V600E
    Solid Tumor
    trametinib + dabrafenib
    Sensitive
    :
    A1
    BRAF V600E
    Melanoma
    encorafenib + binimetinib
    Sensitive
    :
    A1
    BRAF V600E
    Non Small Cell Lung Cancer
    dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Non Small Cell Lung Cancer
    vemurafenib
    Sensitive
    :
    A2
    BRAF V600E
    Glioblastoma
    trametinib + dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    trametinib + dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    vemurafenib + cobimetinib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    vemurafenib
    Sensitive
    :
    A2
    BRAF V600E
    Cutaneous Melanoma
    trametinib + dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Biliary Tract Cancer
    trametinib + dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    trametinib + dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    vemurafenib + cobimetinib
    Sensitive
    :
    A2
    BRAF V600E
    Glioma
    selumetinib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    cobimetinib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    vemurafenib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    trametinib
    Sensitive
    :
    A2
    BRAF V600E
    Astrocytoma
    dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    cobimetinib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    trametinib
    Sensitive
    :
    A2
    BRAF V600E
    Ganglioglioma
    dabrafenib
    Sensitive
    :
    A2
    BRAF V600E
    Cutaneous Melanoma
    pembrolizumab
    Sensitive
    :
    A2
    BRAF V600E
    Cutaneous Melanoma
    nivolumab
    Sensitive
    :
    A2
    BRAF V600E
    Colorectal Cancer
    panitumumab + encorafenib
    Sensitive
    :
    A2